Sumitomo Mitsui Trust Holdings Inc. Raises Stake in Humana Inc. (NYSE:HUM)

Sumitomo Mitsui Trust Holdings Inc. boosted its holdings in shares of Humana Inc. (NYSE:HUM) by 3.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 365,115 shares of the insurance provider’s stock after acquiring an additional 13,067 shares during the period. Sumitomo Mitsui Trust Holdings Inc. owned 0.30% of Humana worth $167,153,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the business. Dorsey & Whitney Trust CO LLC lifted its position in Humana by 2.6% during the 3rd quarter. Dorsey & Whitney Trust CO LLC now owns 817 shares of the insurance provider’s stock valued at $397,000 after acquiring an additional 21 shares during the period. UMB Bank n.a. increased its stake in Humana by 2.8% during the 3rd quarter. UMB Bank n.a. now owns 805 shares of the insurance provider’s stock valued at $392,000 after purchasing an additional 22 shares in the last quarter. Vestcor Inc increased its stake in Humana by 0.3% during the 4th quarter. Vestcor Inc now owns 8,292 shares of the insurance provider’s stock valued at $4,247,000 after purchasing an additional 22 shares in the last quarter. First Financial Corp IN increased its stake in Humana by 7.2% during the 4th quarter. First Financial Corp IN now owns 343 shares of the insurance provider’s stock valued at $157,000 after purchasing an additional 23 shares in the last quarter. Finally, Exencial Wealth Advisors LLC increased its stake in Humana by 4.1% during the 4th quarter. Exencial Wealth Advisors LLC now owns 582 shares of the insurance provider’s stock valued at $298,000 after purchasing an additional 23 shares in the last quarter. 92.38% of the stock is owned by hedge funds and other institutional investors.

Humana Trading Up 0.7 %

HUM stock opened at $314.70 on Tuesday. The company has a quick ratio of 1.59, a current ratio of 1.59 and a debt-to-equity ratio of 0.63. Humana Inc. has a twelve month low of $299.23 and a twelve month high of $541.21. The stock has a market capitalization of $37.97 billion, a price-to-earnings ratio of 15.88, a price-to-earnings-growth ratio of 1.83 and a beta of 0.45. The firm’s fifty day simple moving average is $346.29 and its two-hundred day simple moving average is $427.62.

Humana (NYSE:HUM) last posted its quarterly earnings data on Thursday, January 25th. The insurance provider reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.87). The firm had revenue of $26.46 billion for the quarter, compared to the consensus estimate of $25.47 billion. Humana had a net margin of 2.34% and a return on equity of 19.44%. The company’s revenue was up 17.9% on a year-over-year basis. During the same quarter last year, the firm earned $1.62 EPS. As a group, analysts anticipate that Humana Inc. will post 16.06 earnings per share for the current year.

Humana Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, April 26th. Stockholders of record on Friday, March 29th will be issued a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.12%. The ex-dividend date is Wednesday, March 27th. Humana’s payout ratio is presently 17.86%.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. Deutsche Bank Aktiengesellschaft lowered shares of Humana from a “buy” rating to a “hold” rating and reduced their price objective for the company from $595.00 to $360.00 in a research note on Thursday, January 25th. TheStreet lowered shares of Humana from a “b” rating to a “c+” rating in a research note on Monday, January 8th. Oppenheimer reiterated an “outperform” rating and issued a $630.00 price target on shares of Humana in a research note on Wednesday, January 17th. Truist Financial reiterated a “hold” rating and issued a $550.00 price target on shares of Humana in a research note on Friday, January 19th. Finally, TD Cowen reduced their price target on shares of Humana from $427.00 to $396.00 and set a “buy” rating for the company in a research note on Tuesday, April 2nd. Eleven research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $465.42.

Insider Transactions at Humana

In related news, Director Jorge S. Mesquita purchased 545 shares of the business’s stock in a transaction dated Tuesday, February 20th. The shares were purchased at an average cost of $367.09 per share, for a total transaction of $200,064.05. Following the completion of the acquisition, the director now owns 2,578 shares in the company, valued at approximately $946,358.02. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.29% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.